enGene Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- enGene Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- Canada
- Ticker symbol
- ENGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001980845
Board of directors
-
Gerald A. Brunk · DirectorSince 2023
-
Jason David Hanson · Director · Chief Executive OfficerSince 2023
-
Jasper Bos · DirectorSince 2023
-
Lota S. Zoth · DirectorSince 2023
-
Paul J. Hastings · DirectorSince 2024
-
Richard M. Glickman · DirectorSince 2023
-
Ronald Harold Wilfred Cooper · Director · CEO & PresidentSince 2024
-
Wouter Joustra · DirectorSince 2024
Chief executives
Ronald Harold Wilfred Cooper
· Chief Executive Officer
Since July 2024
Jason David Hanson
· Chief Executive Officer
2023 – 2024
· Former
Board connections
5 of this board's directors also sit on 6 other boards.
- via Jason David Hanson
- via Ronald Harold Wilfred Cooper
- via Lota S. Zoth
- via Wouter Joustra
- via Paul J. Hastings
- via Paul J. Hastings
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2024 | Forbion Growth Management B.V. 10% owner | Open-market purchase | +561,797 | $8.90 | $4,999,993 |
| Oct 8, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +800 | $6.60 | $5,280 |
| Oct 7, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +11,844 | $6.55 | $77,578 |
| Oct 4, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +5,997 | $6.54 | $39,220 |
| Oct 3, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +5,769 | $6.48 | $37,383 |
| Oct 2, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +10,153 | $6.37 | $64,675 |
| Oct 1, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +35,279 | $6.44 | $227,197 |
| Sep 30, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +341,332 | $6.34 | $2,164,045 |
| Sep 27, 2024 | Ronald Harold Wilfred Cooper Director, Officer (Chief Executive Officer) | Open-market purchase | +10,000 | $5.70 | $57,000 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +38,396 | $5.94 | $228,072 |
| Sep 27, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. 10% owner | Open-market purchase | +3,243 | $6.38 | $20,690 |
| May 28, 2024 | Richard M. Glickman Director | Option exercise | +120 | $0.89 | $107 |
| Apr 22, 2024 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Open-market sale | −47,854 | $15.00 | $717,810 |
| Apr 19, 2024 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Open-market sale | −100 | $15.00 | $1,500 |
| Apr 18, 2024 | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC 10% owner | Open-market sale | −4,575 | $15.01 | $68,671 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.